AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02729636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-pad functional electrical stimulation (FES)
Description: Treatment includes two automated phases: optimization of stimulation parameters and application during the walk.~Optimization of stimulation parameters: The stimulator generates short bursts of electrical impulses and sends them to each of the 16 pads of the multi-pad electrode. Each pad is the same size. Pads are sorted in two rows by 8 pads. Common anode is placed under the knee. Based on FES-induced foot movements, automated algorithm suggests parameters which are evaluated by medical doctor/therapist.~Assisted walking: During assisted walking, pattern for plantar flexion is activated in push off phase and pattern for dorsiflexion in swing phase of the gait.
Study NCT02729636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: 2. All study subjects received the conventional stroke rehabilitation program of physiotherapy based on the neurodevelopmental facilitation approach and occupational therapy focused on activities of daily living during the treatment for 60 min a day, 5 days a week, for 4-weeks. Conventional therapy was given by trained therapists and consisted of the following strategies: strategies to joint mobilization and range of motion exercises; exercises to improve strength; strategies to manage spasticity; exercises for increase range of motion, compensatory strategy; strategies to improve balance, and mobility.
Study NCT04683471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator
Description: Neuromodulation
Study NCT04683471 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study NCT02904967 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Extra Blood Draw
Study NCT03542357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 50 mg
Description: CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT03542357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02904967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extra Blood Draw
Study NCT00258154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: 3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
Study NCT00258154 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: 3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
Study NCT00258154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Infanrix(tm) Hexa
Description: 3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
Study NCT00258154 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Infanrix(tm) Hexa
Description: 3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
Study NCT04085003 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular repair or Open surgery
Description: The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
Study NCT01185366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once a day.
Study NCT01185366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg by mouth daily for 4 weeks on / 2 weeks off
Study NCT03580187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine (+)
Description: We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization
Study NCT05538468 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Thirty stroke patients were included in the study. After the demographic information was obtained from all patients who accepted to participate in the study by complying with the inclusion criteria; The kinesiophobia scores of the patients were evaluated, depression severity, postural control and pain severity.
Study NCT03782103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep Clear Solution
Description: Apply topically.
Study NCT03782103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.
Study NCT03782103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZuraPrep Vehicle
Description: Apply topically.
Study NCT00930176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Coagulation FACTOR X
Description: Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
Study NCT04086667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation: The patient is placed in the side-position and a standard manipulation lumbar-roll technique will be applied at the indicated segment dependent on the subgroup indication.
Study NCT00797901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Study NCT02539394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Acetate
Description: Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
Study NCT02539394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hemostatic Matrix Kit
Description: Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
Study NCT02539394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemostatic Matrix Kit
Description: Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
Study NCT01775709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PE tube with Duckbill Valve
Description: PE tube with Duckbill Valve
Study NCT04060992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix 200 MG Oral Tablet [Orilissa]
Description: oral tablet given twice daily
Study NCT04060992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elagolix 200 MG Oral Tablet [Orilissa]
Description: oral tablet given twice daily
Study NCT02129764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02129764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Study NCT03020888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magseed and Sentimag
Description: Magseed marker and Sentimag probe for lesion localization
Study NCT03508453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC14
Description: Monoclonal antibody against CD14
Study NCT03508453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline for injection prepared to be identical to study drug
Study NCT04633876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual coaching
Description: Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
Study NCT04633876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group coaching
Description: Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
Study NCT04633876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
Study NCT02978508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Cream, 5%
Description: Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
Study NCT02978508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elimite
Description: Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
Study NCT03957083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Study NCT01807104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Approach / Posterior Approach
Description: compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
Study NCT01807104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior versus Posterior Approach for total hip replacement
Description: Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
Study NCT06499220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: Spinal Cord Stimulation (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or limbs.
Study NCT03072342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Periodontal Treatment
Study NCT03072342 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Periodontal Treatment
Study NCT03118271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar traction
Study NCT03118271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Study NCT03118271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study NCT03197688 — intervention group
Intervention type: OTHER
Intervention: Notapplicable
Description: Not applicable as non-interventional study
Study NCT05047887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified socket shield technique with autogenous dentin graft material (in one side)
Description: The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then Tooth particles will be demineralized using 2% HNO3 (El-Gomhouria CO. Egypt) for 20 minutes to expose the dentin organic matrix.
Study NCT05047887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified socket shield technique with alloplast graft material (in contralateral side)
Description: The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then alloplast graft will be used
Study NCT04113980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music group
Description: The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
Study NCT04113980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kaleidoscope group
Description: The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
Study NCT04113980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video group
Description: The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
Study NCT01275937 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Esomeprazole
Description: Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
Study NCT01275937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
Study NCT01275937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
Study NCT00562861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram + mood stabilizer
Description: Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
Study NCT00562861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + mood stabilizer
Description: This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
Study NCT03409146 — intervention group
Intervention type: DEVICE
Intervention: Monica Novii Wireless Patch System
Description: The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
Study NCT04597112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique
Description: Myofascial release focuses on reducing pain by easing the tension and tightness in the trigger points. Therapist will gently massage the myofascia and feel for stiff or tightened areas. Normal myofascia should feel pliable and elastic. The therapist will begin massaging and stretching the areas that feel rigid with light manual pressure. The therapist then aids the tissue and supportive sheath in releasing pressure and tightness. The process is repeated multiple times on the same trigger point and on other trigger points until the therapist feels the tension is fully released.
Study NCT04597112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise is recommended by physical therapists for most cervical radiculopathy patients.~In this study, a customized exercise program will be applied for patients with cervical radiculopathy.
Study NCT00655356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (azficel-T)
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face.
Study NCT02454231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of circulating CD14+CD34+cells
Description: intramuscular injection of circulating EPC at leg level
Study NCT02454231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of BM MNC
Description: intramuscular injection of BM MNC at leg level
Study NCT04573647 — intervention group
Intervention type: DRUG
Intervention: Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
Description: Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
Study NCT03230669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cbt4cbt
Description: This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
Study NCT03345342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP6M
Description: Participants will receive intramuscular injection of PP6M.
Study NCT03345342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 350 mg eq.
Description: Participants will receive intramuscular injection of PP3M 350 mg eq.
Study NCT03345342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 525 mg eq.
Description: Participants will receive intramuscular injection of PP3M 525 mg eq.
Study NCT03345342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP1M
Description: Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
Study NCT03345342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT02257606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-TRAVLE training
Study NCT01113047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
Description: Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
Study NCT02797054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored educational materials
Description: The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
Study NCT02797054 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Untailored educational materials
Description: The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention.
Study NCT02797054 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
Study NCT01091428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets
Study NCT01091428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion
Study NCT01963637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gastric tomodensitometry with gas at 3 months and 12 months
Study NCT01554202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory
Study NCT01554202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage
Study NCT03579654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Proscavax
Description: Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
Study NCT00291733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: 500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
Study NCT00291733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tabl
Study NCT00349271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: Stem cell
Study NCT00349271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastime (G-CSF)
Description: Filgrastime (G-CSF)
Study NCT01600963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm B Double-blind Phase: Placebo
Description: Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
Study NCT00349271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standart therapy
Description: All drug with clinical evidence of benefical effect in Chagas disease
Study NCT04955860 — intervention group
Intervention type: OTHER
Intervention: Dental model analysis
Description: No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.